References
- Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R.
Pre-eclampsia. Lancet. 2010 Aug;376(9741):631–44.
- Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk
of cardiovascular disease and cancer in later life: Systematic review
and meta-analysis. Br J Med. 2007 Nov;335(7627):974
- Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN,
Nirantharakumar K, et al. Association between the reproductive health
of young women and cardiovascular disease in later life: umbrella
review. BMJ. 2020 Oct;371:m3502.
- Brown MC, Best KE, Pearce MS, Waugh J, Robson SC, Bell R.
Cardiovascular disease risk in women with pre-eclampsia: systematic
review and meta-analysis. Eur J Epidemiol. 2013 Jan;28(1):1–19.
- Smith GN, Pudwell J, Walker M, Wen S-W. Ten-year, thirty-year, and
lifetime cardiovascular disease risk estimates following a pregnancy
complicated by preeclampsia. J Obstet Gynaecol Can. 2012
Sep;34(9):830–5.
- McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ.
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review
and meta-analyses. Am Heart J. 2008 Nov;156(5):918–30.
- Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and
cardiovascular disease death: prospective evidence from the
child health and development studies cohort. Hypertension. 2010
Jul;56(1):166–71.
- Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health
after maternal placental syndromes (CHAMPS): population-based
retrospective cohort study. Lancet. 2005 Nov;366(9499):1797–803.
- Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk
of ischaemic heart disease: a retrospective cohort study of 129,290
births. Lancet. 2001 Jun;357(9273):2002–6.
- Smith GN, Walker MC, Liu A, Wen SW, Swansburg M, Ramshaw H, et al. A
history of preeclampsia identifies women who have underlying
cardiovascular risk factors. Am J Obstet Gynecol. 2009
Jan;200(1):58.e1-8.
- Heidema WM, Scholten RR, Lotgering FK, Spaanderman MEA. History of
preeclampsia is more predictive of cardiometabolic and cardiovascular
risk factors than obesity. Eur J Obstet Gynecol Reprod Biol. 2015 Nov;
194:189–93.
- Yinon Y, Kingdom JCP, Odutayo A, Moineddin R, Drewlo S, Lai V, et al.
Vascular dysfunction in women with a history of preeclampsia and
intrauterine growth restriction: insights into future vascular risk.
Circulation. 2010 Nov;122(18):1846–53.
- Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC.
Endothelial function and circulating biomarkers are disturbed in women
and children after preeclampsia. Hypertension. 2011 Jul;58(1):63–9.
- Fillion A, Guerby P, Menzies D, Lachance C, Comeau M-P, Bussières M-C,
et al. Pathological investigation of placentas in preeclampsia (the
PEARL study). Hypertens Pregnancy. 2021 Feb;40(1):56–62.
- Weiner E, Feldstein O, Tamayev L, Grinstein E, Barber E, Bar J, et al.
Placental histopathological lesions in correlation with neonatal
outcome in preeclampsia with and without severe features. Pregnancy
Hypertens. 2018 Apr;12:6–10.
- Kovo M, Schreiber L, Ben-Haroush A, Gold E, Golan A, Bar J. The
placental component in early-onset and late-onset preeclampsia in
relation to fetal growth restriction. Prenat Diagn. 2012
Jul;32(7):632–7.
- Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia:
pathophysiology and clinical implications. BMJ. 2019 Jul;366:l2381.
- Schneider H. Placental dysfunction as a key element in the
pathogenesis of preeclampsia. Dev Period Med. 2017;21(4):309–16.
- Benton SJ, Leavey K, Grynspan D, Cox BJ, Bainbridge SA. The clinical
heterogeneity of preeclampsia is related to both placental gene
expression and placental histopathology. Am J Obstet Gynecol. 2018
Dec;219(6): 604.e1-604.e25.
- Falco ML, Sivanathan J, Laoreti A, Thilaganathan B, Khalil A.
Placental histopathology associated with pre-eclampsia: systematic
review and meta-analysis. Ultrasound Obstet Gynecol. 2017
Sep;50(3):295–301.
- Catov JM, Muldoon MF, Reis SE, Ness RB, Nguyen LN, Yamal J-M, et al.
Preterm birth with placental evidence of malperfusion is associated
with cardiovascular risk factors after pregnancy: a prospective cohort
study. BJOG. 2018 Jul;125(8):1009–17.
- Brosens I, Benagiano M, Puttemans P, D’Elios MM, Benagiano G. The
placental bed vascular pathology revisited: a risk indicator for
cardiovascular disease. J Matern Fetal Neonatal Med. 2019
May;32(9):1556–64.
- Stevens DU, Smits MP, Bulten J, Spaanderman MEA, van Vugt JMG,
Al-Nasiry S. Prevalence of hypertensive disorders in women after
preeclamptic pregnancy associated with decidual vasculopathy.
Hypertens pregnancy. 2015;34(3):332–41.
- Stevens DU, Al-Nasiry S, Fajta MM, Bulten J, van Dijk AP, van der
Vlugt MJ, et al. Cardiovascular and thrombogenic risk of decidual
vasculopathy in preeclampsia. Am J Obstet Gynecol. 2014
Jun;210(6):545.e1-6.
- Veerbeek JHW, Smit JG, Koster MPH, Post Uiterweer ED, van Rijn BB,
Koenen S V, et al. Maternal cardiovascular risk profile after
placental abruption. Hypertension. 2013 Jun;61(6):1297–301.
- Parks WT, Catov JM. The placenta as a window to maternal vascular
health. Obstet Gynecol Clin North Am. 2020 Mar;47(1):17–28.
- Park K, Minissian MB, Wei J, Saade GR, Smith GN. Contemporary clinical
updates on the prevention of future cardiovascular disease in women
who experience adverse pregnancy outcomes. Clin Cardiol. 2020
Jun;43(6):553–9.
- Cusimano MC, Pudwell J, Roddy M, Cho C-KJ, Smith GN. The maternal
health clinic: an initiative for cardiovascular risk identification in
women with pregnancy-related complications. Am J Obstet Gynecol.
2014;210(5):438.e1-438.e9.
- Smith GN. The Maternal Health Clinic: Improving women’s cardiovascular
health. Semin Perinatol. 2015 Jun;39(4):316–9.
- Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian
Hypertensive Disorders of Pregnancy Working Group. Diagnosis,
evaluation, and management of the hypertensive disorders of pregnancy:
executive summary. J Obstet Gynaecol Can. 2014 May;36(5):416-41.
- Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et
al. A new and improved population-based Canadian reference for birth
weight for gestational age. Pediatrics. 2001 Aug;108(2):E35.
- Warrander LK, Batra G, Bernatavicius G, Greenwood SL, Dutton P, Jones
RL, Sibley CP, Heazell AE. Maternal perception of reduced fetal
movements is associated with altered placental structure and function.
PLoS One. 2012;7(4):e34851.
- Benton SJ, Lafreniere AJ, Grynspan D, Bainbridge SA. A synoptic
framework and future directions for placental pathology reporting.
Placenta. 2019 Feb;77:46-57.
- Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson
PWF, et al. Prediction of lifetime risk for cardiovascular disease by
risk factor burden at 50 years of age. Circulation. 2006
Feb;113(6):791–8.
- Holzman CB, Senagore P, Xu J, Dunietz GL, Strutz KL, Tian Y, et al.
Maternal risk of hypertension 7-15 years after pregnancy: clues from
the placenta. BJOG. 2021 Apr;128(5):827–36.
- Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in
human pregnancy: facts and controversies. Placenta.
2006;27(9–10):939–58.
- Bustamante Helfrich B, Chilukuri N, He H, Cerda SR, Hong X, Wang G, et
al. Maternal vascular malperfusion of the placental bed associated
with hypertensive disorders in the Boston Birth Cohort. Placenta. 2017
Apr; 52:106–13.
- Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G,
Romundstad PR. Prepregnancy cardiovascular risk factors as predictors
of pre-eclampsia: population-based cohort study. BMJ. 2007
Nov;335(7627):978.
- Pavan L, Tsatsaris V, Hermouet A, Therond P, Evain-Brion D, Fournier
T. Oxidized low-density lipoproteins inhibit trophoblastic cell
invasion. J Clin Endocrinol Metab. 2004 Apr;89(4):1969–72.
- Pavan L, Hermouet A, Tsatsaris V, Thérond P, Sawamura T, Evain-Brion
D, et al. Lipids from oxidized low-density lipoprotein modulate human
trophoblast invasion: involvement of nuclear liver X receptors.
Endocrinology. 2004 Oct;145(10):4583–91.
- Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity
and preeclampsia: the potential role of inflammation. Obstet Gynecol.
2001 Nov;98(5 Pt 1):757–62.
- Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and
triglycerides partially mediate the effect of prepregnancy body mass
index on the risk of preeclampsia. Am J Epidemiol. 2005
Dec;162(12):1198–206.
- Otun HA, Lash GE, Innes BA, Bulmer JN, Naruse K, Hannon T, et al.
Effect of tumour necrosis factor-α in combination with interferon-γ on
first trimester extravillous trophoblast invasion. J Reprod Immunol.
2011 Jan;88(1):1–11.
- Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al.
Short- and long-term changes in plasma inflammatory markers associated
with preeclampsia. Hypertension. 2004 Nov;44(5):708–14.
- Garrido-Gimenez C, Mendoza M, Cruz-Lemini M, Galian-Gay L,
Sanchez-Garcia O, Granato C, et al. Angiogenic factors and long-term
cardiovascular risk in women that developed preeclampsia during
pregnancy. Hypertension. 2020 Dec;76(6):1808–16.
- Benschop L, Schalekamp-Timmermans S, Broere-Brown ZA, Roeters van
Lennep JE, Jaddoe VW V, Roos-Hesselink JW, et al. Placental growth
factor as an indicator of maternal cardiovascular risk after
pregnancy. Circulation. 2019 Apr;139(14):1698–709.
- Akhter T, Wikström A-K, Larsson M, Larsson A, Wikström G, Naessen T.
Association between angiogenic factors and signs of arterial aging in
women with pre-eclampsia. Ultrasound Obstet Gynecol. 2017
Jul;50(1):93–9.
- Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Luksha L,
Kublickiene K. Placental growth factor is a potent vasodilator of rat
and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008
Mar;294(3):H1381-7.
- Amraoui F, Spijkers L, Hassani Lahsinoui H, Vogt L, van der Post J,
Peters S, Afink G, Ris-Stalpers C, van den Born BJ. SFlt-1 elevates
blood pressure by augmenting endothelin-1-mediated vasoconstriction in
mice. PLoS One. 2014 Mar 14;9(3):e91897.
- Sills A, Steigman C, Ounpraseuth ST, Odibo I, Sandlin AT, Magann EF.
Pathologic examination of the placenta: recommended versus observed
practice in a university hospital. Int J Womens Health. 2013 Jun
12;5:309–12.
Table 1. Maternal characteristics of the study participants as a
combined cohort and by individual study site. Presented as mean ± SD,
median [IQR] or n (%).